Preclinical evaluation of potential nilotinib cardiotoxicity
- PMID: 21129774
- DOI: 10.1016/j.leukres.2010.11.001
Preclinical evaluation of potential nilotinib cardiotoxicity
Abstract
In vitro, concentrations ≥ 10 μM of nilotinib were needed to induce markers of cytotoxicity, apoptosis, and endoplasmic reticulum stress in both neonatal rat ventricular myocytes, a putative target tissue, and non-target heart fibroblasts, indicating a lack of cardiomyocyte-specific nilotinib toxicity in vitro. In rats, oral nilotinib treatment at 80 mg/kg for 4 weeks induced increased heart weight; however, this was not associated with relevant histopathological changes or effects on heart function. Thus, nilotinib at and above clinically relevant concentrations (4.27 μM) did not induce overt cardiovascular pathologies or heart failure in vitro or in vivo under study conditions.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Comment in
-
Nilotinib cardiac toxicity: should we still be concerned?Leuk Res. 2011 May;35(5):577-8. doi: 10.1016/j.leukres.2011.01.021. Epub 2011 Feb 17. Leuk Res. 2011. PMID: 21333353 No abstract available.
Similar articles
-
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies.Leuk Res. 2010 Sep;34(9):1180-8. doi: 10.1016/j.leukres.2010.01.004. Epub 2010 Jan 31. Leuk Res. 2010. PMID: 20122731
-
Blockage of endoplasmic reticulum stress attenuates nilotinib-induced cardiotoxicity by inhibition of the Akt-GSK3β-Nox4 signaling.Eur J Pharmacol. 2018 Mar 5;822:85-94. doi: 10.1016/j.ejphar.2018.01.011. Epub 2018 Jan 31. Eur J Pharmacol. 2018. PMID: 29355557
-
Nilotinib induces ER stress and cell death in H9c2 cells.Physiol Res. 2016 Dec 21;65(Suppl 4):S505-S514. doi: 10.33549/physiolres.933504. Physiol Res. 2016. PMID: 28006933
-
Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes.J Pharmacol Toxicol Methods. 2017 Sep;87:48-52. doi: 10.1016/j.vascn.2017.05.003. Epub 2017 May 23. J Pharmacol Toxicol Methods. 2017. PMID: 28549786
-
Optimizing adult mesenchymal stem cells for heart repair.J Mol Cell Cardiol. 2007 Feb;42(2):283-4. doi: 10.1016/j.yjmcc.2006.11.003. Epub 2006 Dec 18. J Mol Cell Cardiol. 2007. PMID: 17174974 Review. No abstract available.
Cited by
-
AXL Inhibition in Macrophages Stimulates Host-versus-Leukemia Immunity and Eradicates Naïve and Treatment-Resistant Leukemia.Cancer Discov. 2021 Nov;11(11):2924-2943. doi: 10.1158/2159-8290.CD-20-1378. Epub 2021 Jun 8. Cancer Discov. 2021. PMID: 34103328 Free PMC article.
-
Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications.Front Cardiovasc Med. 2023 Sep 8;10:1150569. doi: 10.3389/fcvm.2023.1150569. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37745115 Free PMC article. Review.
-
Elevation of pulmonary artery pressure as a complication of nilotinib therapy for chronic myeloid leukemia.Int J Hematol. 2012 Jul;96(1):132-5. doi: 10.1007/s12185-012-1103-0. Epub 2012 May 26. Int J Hematol. 2012. PMID: 22639052
-
Spontaneously occurring cardiovascular lesions in commonly used laboratory animals.Cardiooncology. 2019 Jun 3;5:6. doi: 10.1186/s40959-019-0040-y. eCollection 2019. Cardiooncology. 2019. PMID: 32154013 Free PMC article. Review.
-
Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.Curr Hematol Malig Rep. 2020 Feb;15(1):20-30. doi: 10.1007/s11899-020-00560-x. Curr Hematol Malig Rep. 2020. PMID: 32078113 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources